News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-02-27 4:50:5 am U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma BusinessWire
2024-02-26 4:45:0 pm U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma GlobeNewswire
2024-02-26 2:21:0 am Transactions in connection with share buy-back program GlobeNewswire
2024-02-23 2:50:0 pm Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons GlobeNewswire
2024-02-23 2:35:0 pm Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab GlobeNewswire
2024-02-15 7:47:53 am Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript Insider Monkey
2024-02-15 5:0:1 am Genmab: Growth Is Still a Better Choice GuruFocus.com
2024-02-15 3:0:0 am Notice to Convene the Annual General Meeting of Genmab A/S GlobeNewswire
2024-02-14 11:9:0 am Genmab Files Annual Report with the U.S. Securities and Exchange Commission GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information